ArticleBMC pediatrics2025
The value of MMP-7 combined with serological markers in diagnosing liver fibrosis in children with biliary atresia.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo explore the diagnostic value of Matrix Metallopeptidase 7 (MMP-7) alongside serological markers in identifying liver fibrosis in children with biliary atresia (BA).
methodsA retrospective study was conducted to analyze the general information, liver fibrosis stage, and laboratory results, including MMP-7, of children with BA who underwent Kasai portoenterostomy between 2022 and 2024 at two Chinese hospitals. The aspartate aminotransferase to platelet ratio index (APRI), Fibrosis 4 Score (FIB-4), and infant biliary atresia liver fibrosis (iBALF) score were calculated according to the formula.
resultsSignificant differences in APRI, FIB-4, iBALF score, and MMP-7 were observed across fibrosis stages.When differentiating different stages of liver fibrosis, FIB-4 demonstrated the highest AUC values (0.807 and 0.815) for identifying liver fibrosis stages ≥ F2 and ≥ F3, and the optimal cut-off values were 0.073 and 0.105. For evaluating stage F4, MMP-7 showed the highest AUC value of 0.793, with an optimal cut-off of 68.94. Combining MMP-7 with other markers improved diagnostic accuracy, particularly MMP-7 + iBALF score for cirrhosis (F4: AUC = 0.844).
conclusionSerological markers like FIB-4, iBALF score, and MMP-7 can reflect various levels of liver fibrosis. Among these, the combination of MMP-7 and iBALF score is the most effective in differentiating liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.